JP2013010790A5 - - Google Patents

Download PDF

Info

Publication number
JP2013010790A5
JP2013010790A5 JP2012223526A JP2012223526A JP2013010790A5 JP 2013010790 A5 JP2013010790 A5 JP 2013010790A5 JP 2012223526 A JP2012223526 A JP 2012223526A JP 2012223526 A JP2012223526 A JP 2012223526A JP 2013010790 A5 JP2013010790 A5 JP 2013010790A5
Authority
JP
Japan
Prior art keywords
acid
solvate
pharmaceutically acceptable
methylpropyl
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012223526A
Other languages
English (en)
Japanese (ja)
Other versions
JP5503709B2 (ja
JP2013010790A (ja
Filing date
Publication date
Priority claimed from GBGB0414093.5A external-priority patent/GB0414093D0/en
Application filed filed Critical
Publication of JP2013010790A publication Critical patent/JP2013010790A/ja
Publication of JP2013010790A5 publication Critical patent/JP2013010790A5/ja
Application granted granted Critical
Publication of JP5503709B2 publication Critical patent/JP5503709B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2012223526A 2004-06-23 2012-10-05 オキシトシン受容体アンタゴニストとしてのピペラジンジオン Expired - Fee Related JP5503709B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0414093.5 2004-06-23
GBGB0414093.5A GB0414093D0 (en) 2004-06-23 2004-06-23 Novel compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007517197A Division JP5405019B2 (ja) 2004-06-23 2005-06-21 オキシトシン受容体アンタゴニストとしてのピペラジンジオン

Publications (3)

Publication Number Publication Date
JP2013010790A JP2013010790A (ja) 2013-01-17
JP2013010790A5 true JP2013010790A5 (enExample) 2014-03-27
JP5503709B2 JP5503709B2 (ja) 2014-05-28

Family

ID=32800053

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007517197A Expired - Fee Related JP5405019B2 (ja) 2004-06-23 2005-06-21 オキシトシン受容体アンタゴニストとしてのピペラジンジオン
JP2012223526A Expired - Fee Related JP5503709B2 (ja) 2004-06-23 2012-10-05 オキシトシン受容体アンタゴニストとしてのピペラジンジオン

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007517197A Expired - Fee Related JP5405019B2 (ja) 2004-06-23 2005-06-21 オキシトシン受容体アンタゴニストとしてのピペラジンジオン

Country Status (30)

Country Link
US (9) US7550462B2 (enExample)
EP (2) EP1758886B1 (enExample)
JP (2) JP5405019B2 (enExample)
KR (1) KR101186447B1 (enExample)
CN (1) CN1972924B (enExample)
AR (1) AR049405A1 (enExample)
AU (1) AU2005256470B2 (enExample)
BR (1) BRPI0512376A (enExample)
CA (1) CA2571527C (enExample)
CY (1) CY1116183T1 (enExample)
DK (1) DK1758886T3 (enExample)
ES (1) ES2537801T3 (enExample)
GB (1) GB0414093D0 (enExample)
HK (1) HK1208669A1 (enExample)
HR (1) HRP20150401T1 (enExample)
HU (1) HUE025869T2 (enExample)
IL (2) IL179905A0 (enExample)
MA (1) MA28675B1 (enExample)
MX (1) MXPA06014545A (enExample)
MY (1) MY143578A (enExample)
NO (1) NO338769B1 (enExample)
NZ (1) NZ551733A (enExample)
PE (1) PE20060477A1 (enExample)
PL (1) PL1758886T3 (enExample)
PT (1) PT1758886E (enExample)
RU (1) RU2382038C2 (enExample)
SI (1) SI1758886T1 (enExample)
TW (1) TWI348466B (enExample)
WO (1) WO2006000399A1 (enExample)
ZA (1) ZA200610022B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0130677D0 (en) 2001-12-21 2002-02-06 Glaxo Group Ltd Medicaments and novel compounds
ES2397327T3 (es) 2002-06-17 2013-03-06 Thrasos, Inc. Compuestos asociados a un dominio único de TDF y análogos de los mismos
GB0314738D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
AU2005265098B2 (en) 2004-06-17 2012-02-23 Thrasos Innovation, Inc. TDF-related compounds and analogs thereof
GB0414100D0 (en) * 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414093D0 (en) * 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
HUE026634T2 (en) 2005-09-20 2016-07-28 Thrasos Innovation Inc TDF-related compounds and analogues thereof
US8716286B2 (en) 2009-10-30 2014-05-06 Glaxo Group Limited Crystalline forms of (3R, 6R)-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione
AU2017205254B2 (en) 2016-01-04 2021-05-20 Xoma (Us) Lcc Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
WO2017203012A1 (en) * 2016-05-27 2017-11-30 Glaxosmithkline Intellectual Property (No.2) Limited Epelsiban for use in the treatment of adenomyosis
WO2018015497A2 (en) 2016-07-21 2018-01-25 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
RU2762019C1 (ru) * 2018-05-29 2021-12-14 Као Корпорейшн Способ оценки функциональной способности листа вызывать ощущение комфорта и лист, вызывающий ощущение комфорта
EP4595974A3 (en) 2018-10-22 2025-08-13 William D. Carlson Therapeutic combinations of tdfrps and additional agents and methods of use
CN114667141A (zh) 2019-09-03 2022-06-24 奥布赛瓦股份公司 用于促进胚胎移植和预防流产的催产素拮抗剂给药方案
WO2021160597A1 (en) 2020-02-10 2021-08-19 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596819A (en) 1984-01-23 1986-06-24 Warner-Lambert Company Modified tripeptides
DE3830096A1 (de) 1988-09-03 1990-03-15 Hoechst Ag Piperazindione mit psychotroper wirkung
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5817751A (en) 1994-06-23 1998-10-06 Affymax Technologies N.V. Method for synthesis of diketopiperazine and diketomorpholine derivatives
GB2326639A (en) 1997-06-18 1998-12-30 Merck & Co Inc Piperazine Oxytocin Receptor Antagonists
HUP0101810A3 (en) 1998-01-27 2002-05-28 Aventis Pharm Prod Inc Substituted oxoazaheterocyclyl factor xa inhibitors and pharmaceutical compositions containing them
JP2002501944A (ja) 1998-01-29 2002-01-22 アヴェンティス ファーマシューティカルズ プロダクツ インコーポレイテッド N−[(脂肪族又は芳香族)カルボニル]−2−アミノアセトアミド化合物及び環化化合物の製造方法
EP1070084A4 (en) 1998-03-16 2001-09-12 Ontogen Corp PIPERAZINE AS INHIBITORS OF FRUKTOSE-1,6-BISPHOSPHATASE (FBPASE)
GB0130677D0 (en) * 2001-12-21 2002-02-06 Glaxo Group Ltd Medicaments and novel compounds
GB0314738D0 (en) * 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
GB0314733D0 (en) * 2003-06-24 2003-07-30 Glaxo Group Ltd Medicaments
GB0414092D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414100D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414093D0 (en) * 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0428235D0 (en) 2004-12-23 2005-01-26 Glaxo Group Ltd Novel compounds

Similar Documents

Publication Publication Date Title
JP2013010790A5 (enExample)
TN2018000130A1 (en) N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
JP2011510929A5 (enExample)
JP2015509535A5 (enExample)
JP2016516699A5 (enExample)
JP2015535839A5 (enExample)
CY1122748T1 (el) Νεα θεραπεια
JP2016532677A5 (enExample)
JP2011219498A5 (enExample)
JP2016521710A5 (enExample)
JP2015535847A5 (enExample)
JP2012502890A5 (enExample)
JP2013529179A5 (enExample)
JP2015537020A5 (enExample)
JP2018529657A5 (enExample)
JP2017515844A5 (enExample)
JP2015520729A5 (enExample)
EP4201399A3 (en) Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
AU2013332205B2 (en) Solid forms of Nilotinib hydrochloride
JP2018534286A5 (enExample)
WO2018035346A8 (en) KINASE INHIBITING COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING CANCER
JP2013514974A5 (enExample)
MX2012003720A (es) N-((1r,2s,5r)-5-(tert-butilamino)-2-((s)-3-(7-tert-butilpirazolo[ 1,5-a][1,3,5]triazin-4-ilamino)-2-oxopirrolidin-1-il)ciclohexil)a cetamida, un modulador dual de la actividad del receptor de quimiocinas, formas cristalinas y procesos.
JP2017502063A5 (enExample)
MX2021007800A (es) Composiciones y metodos para usar 2-(4-clorofenil)-n-((2-(2,6-diox opiperidin-3-il)-1-ox-oisoindolin-5il)metil)-2,2-difluoroacetamid a.